SG11202011353XA - Stable fusion protein formulation - Google Patents

Stable fusion protein formulation

Info

Publication number
SG11202011353XA
SG11202011353XA SG11202011353XA SG11202011353XA SG11202011353XA SG 11202011353X A SG11202011353X A SG 11202011353XA SG 11202011353X A SG11202011353X A SG 11202011353XA SG 11202011353X A SG11202011353X A SG 11202011353XA SG 11202011353X A SG11202011353X A SG 11202011353XA
Authority
SG
Singapore
Prior art keywords
fusion protein
protein formulation
stable fusion
stable
formulation
Prior art date
Application number
SG11202011353XA
Inventor
Murali Jayaraman
M Lakshmi Kanakadurga
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of SG11202011353XA publication Critical patent/SG11202011353XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202011353XA 2018-05-25 2019-05-24 Stable fusion protein formulation SG11202011353XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201841019605 2018-05-25
PCT/IN2019/050408 WO2019224842A1 (en) 2018-05-25 2019-05-24 Stable fusion protein formulation

Publications (1)

Publication Number Publication Date
SG11202011353XA true SG11202011353XA (en) 2020-12-30

Family

ID=68616762

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011353XA SG11202011353XA (en) 2018-05-25 2019-05-24 Stable fusion protein formulation

Country Status (10)

Country Link
US (1) US20210188941A1 (en)
EP (1) EP3801605A4 (en)
JP (2) JP7449243B2 (en)
CN (1) CN112512561A (en)
AU (1) AU2019274826A1 (en)
BR (1) BR112020023860A2 (en)
CO (1) CO2020016008A2 (en)
SG (1) SG11202011353XA (en)
WO (1) WO2019224842A1 (en)
ZA (1) ZA202007491B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022195505A1 (en) * 2021-03-16 2022-09-22 Kashiv Biosciences, Llc Novel formulation of fusion protein
CN115400076B (en) * 2022-08-17 2023-09-05 安徽安科生物工程（集团）股份有限公司 Recombinant human growth hormone-Fc fusion protein injection formulation
WO2024191785A1 (en) 2023-03-10 2024-09-19 Genentech, Inc. Fusions with proteases and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2291264T3 (en) * 1991-12-20 2008-03-01 Novo Nordisk A/S STABILIZED PHARMACEUTICAL FORMULATION UNDERSTANDING A GROWTH AND HISTIDINE HORMONE.
ES2436616T5 (en) * 2005-12-20 2022-05-27 Bristol Myers Squibb Co Stable protein formulations
BRPI0620316A2 (en) * 2005-12-21 2011-11-08 Wyeth Corp Low viscosity protein formulations and their uses
CN101199484B (en) 2006-12-14 2011-08-17 上海抗体药物国家工程研究中心有限公司 CTLA4-Ig fusion protein preparation
ES2826894T3 (en) * 2010-02-19 2021-05-19 Xencor Inc New immunoadhesins CTLA4-IG
EP2545073B1 (en) * 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Ctla4 proteins and their uses
EP2727602A1 (en) * 2012-10-31 2014-05-07 Takeda GmbH Method for preparation of a high concentration liquid formulation of an antibody
BR112015009961B1 (en) * 2012-11-01 2020-10-20 Abbvie Inc. binding protein capable of binding to dll4 and vegf, as well as a composition comprising it as a composition comprising it
KR102386735B1 (en) * 2015-11-06 2022-04-14 주식회사 제넥신 Formulation for modified interleukin-7 fusion protein
WO2017095848A1 (en) * 2015-11-30 2017-06-08 Medimmune, Llc Optimized ratios of amino acids and sugars as amorphous stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
JOP20190260A1 (en) * 2017-05-02 2019-10-31 Merck Sharp & Dohme Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof

Also Published As

Publication number Publication date
CN112512561A (en) 2021-03-16
WO2019224842A1 (en) 2019-11-28
ZA202007491B (en) 2022-09-28
AU2019274826A1 (en) 2021-01-07
CO2020016008A2 (en) 2021-01-29
JP2024023468A (en) 2024-02-21
BR112020023860A2 (en) 2021-04-13
EP3801605A1 (en) 2021-04-14
JP7449243B2 (en) 2024-03-13
JP2021524470A (en) 2021-09-13
EP3801605A4 (en) 2022-03-16
US20210188941A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
IL281954A (en) Heterodimeric fc-fused proteins
EP3880814A4 (en) Fusion protein
SG11202011743SA (en) Fusion proteins comprising progranulin
SG11202012004SA (en) Rna-targeting fusion protein compositions and methods for use
EP3757218A4 (en) Fusion protein
MA50908A (en) VEGFR-FC FUSION PROTEIN FORMULATIONS
EP3199179A4 (en) Recombinant fusion protein formulation
HK1247933A1 (en) Fusion protein containing bdnf
SG11202109277WA (en) Stable protein formulations
EP3199555A4 (en) Recombinant fusion protein formulation
EP3561058A4 (en) Fusion protein including bdnf
ZA202007491B (en) Stable fusion protein formulation
EP3585409A4 (en) Csf1r-based chimeric proteins
DK3737402T3 (en) Modificeret protein
ZA202003845B (en) Fusion proteins
EP3722305A4 (en) Hm-3 fusion protein and use thereof
SG11202101904UA (en) Spd-1 variant - fc fusion proteins
SG11202104912SA (en) Fusion protein and use thereof
ZA202102533B (en) Fusion protein
EP3419651C0 (en) Improved naglu fusion protein formulation
IL273271A (en) Fusion protein comprising an fgf-18 moiety
IL281088A (en) Flt3l-based chimeric proteins
IL263842A (en) Tatk -cdkl5 fusion proteins, compositions, formulations, and use thereof
IL283229A (en) High concentration protein formulation
EP3585410A4 (en) Vsig8-based chimeric proteins